Emphysema News and Research

Latest Emphysema News and Research

A1-PI treatment slows progression of emphysema in patients with AATD

Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.

22 May 2013

Systemic inflammation is linked with depression in COPD patients, say researchers

Depression is common in patients with chronic obstructive pulmonary disease (COPD) and has been linked with disease severity and impaired quality of life. Now, for the first time, researchers at the University of Pittsburgh have linked the systemic inflammation associated with COPD with depression in these patients.

22 May 2013

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis.

21 May 2013

Lung Volume Reduction Coil may play key role in treatment of emphysema, study finds

A small, easily implantable device called the Lung Volume Reduction Coil may play a key role in the treatment of two types of emphysema, according to a study conducted in Europe. Results of the study indicate the beneficial effects of the device persist more than a year after initial treatment.

21 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

ACOEM provides tools, resources to help employers identify and respond to impact of COPD

Awareness campaign for the workplace provides tools and information on preventing and managing chronic obstructive pulmonary disease - the third leading cause of death in the U.S.

12 Apr 2013

IDIBELL signs agreement with Histocell to use patent for acute pulmonary diseases with stem cells

The Bellvitge Biomedical Research Institute has signed a licensing agreement with the Spanish biotech company Histocell to make use of a patent for the treatment of acute pulmonary diseases with mesenchymal stem cells.

28 Mar 2013

SLU researcher studies effect of bitter melon extract on treating cancer

A Saint Louis University researcher has received a $39,425 grant from the Lottie Caroline Hardy Charitable Trust to continue her research on treating cancer with a natural substance -- the extract taken from a vegetable that is part of her diet.

24 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Research findings could lead to new treatments for lung disorders in premature babies

Researchers at Yale School of Medicine have made major discoveries that could lead to new treatments for lung disorders in premature babies. In a mouse study, the team located key molecules that switch on stress pathways in preterm lung disorders, and also found that when parts of these pathways were blocked with a pain drug, lung damage was prevented or reversed.

21 Mar 2013

Chronic obstructive pulmonary disease (COPD) inflammatory subtypes: an interview with Dr Vanessa McDonald, University of Newcastle, Australia

COPD is defined as a preventable and treatable disease associated with significant extrapulmonary consequences that may contribute to severity. The pulmonary component of COPD is characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive with an abnormal inflammatory response of the lungs to noxious particles (GOLD Strategy Document). Airflow obstruction in COPD is not highly variable and largely irreversible.

8 Mar 2013

PneumRx initiates RePneu LVRC pivotal study in severe emphysema

PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRx's Lung Volume Reduction Coils (LVRCs) for severe emphysema.

25 Feb 2013

UAB becomes first in America to test experimental therapy for emphysema

A patient at the University of Alabama at Birmingham (UAB) became the first person in America to undergo an investigational therapy for emphysema that uses a foam sealant sprayed into the lungs.

23 Feb 2013

Optimal lung cancer screening nodule size questioned

Researchers challenge the definition of a positive result in first-round lung cancer screening with low-dose computed tomography in the Annals of Internal Medicine.

19 Feb 2013

Researchers identify new molecular pathway involved in alveoli growth

In a study of mice, researchers at Johns Hopkins have identified a new molecular pathway involved in the growth of tiny air sacs called alveoli that are crucial for breathing. The scientists say their experiments may lead to the first successful treatments to regrow the air sacs in people who suffer from diseases such as emphysema in which the air sacs have been destroyed by years of smoking.

15 Feb 2013

Marijuana may double stroke risk in young adults

Marijuana, the most widely used illicit drug, may double stroke risk in young adults, according to research presented at the American Stroke Association's International Stroke Conference 2013.

9 Feb 2013

Older adults with COPD more frequently use benzodiazepines

A popular class of drugs commonly used to treat sleep and mood symptoms continues to be frequently prescribed despite being known to have potentially life-threatening side effects.

9 Feb 2013

Emphysema News and Research

Latest Emphysema News and Research

A1-PI treatment slows progression of emphysema in patients with AATD

Systemic inflammation is linked with depression in COPD patients, say researchers

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Lung Volume Reduction Coil may play key role in treatment of emphysema, study finds

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

ACOEM provides tools, resources to help employers identify and respond to impact of COPD

IDIBELL signs agreement with Histocell to use patent for acute pulmonary diseases with stem cells

SLU researcher studies effect of bitter melon extract on treating cancer

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Research findings could lead to new treatments for lung disorders in premature babies

Chronic obstructive pulmonary disease (COPD) inflammatory subtypes: an interview with Dr Vanessa McDonald, University of Newcastle, Australia

PneumRx initiates RePneu LVRC pivotal study in severe emphysema

UAB becomes first in America to test experimental therapy for emphysema

Optimal lung cancer screening nodule size questioned

Researchers identify new molecular pathway involved in alveoli growth

Marijuana may double stroke risk in young adults

Older adults with COPD more frequently use benzodiazepines

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Emphysema News and Research

Latest Emphysema News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in